NASDAQ · Health care

Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Corp. brought in $194K of revenue over the twelve months to May 31, 2026, down 68.5% from a year earlier. It posted a net loss of $7.7M. In fiscal 2025 capital spending exceeded operating cash flow by $10.5M. At May 31, 2026 it held $3.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 13, 2026.

Price

$3.28

-4.65% on the day · September 25, 2026

52-week range $2.80 to $21.60

Market cap

$5.4M

Revenue (last 12 months)

$194K

-68.5% year on year

Net margin

-3,985.6%

What Lexaria Bioscience Corp. does

Lexaria Bioscience Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LEXX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$705.9K	-$11.9M	-$11.9M	-$0.66	-$10.5M
2024	$464.3K	-$5.8M	-$5.8M	-$0.47	-$5M
2023	$226.2K	-$6.5M	-$6.7M	-$1.01	-$5.9M
2022	$255.4K	-$6.6M	-$7.3M	n/a	-$4.9M
2021	$722.7K	-$5.7M	-$4M	-$0.95	n/a
2020	$384.5K	n/a	-$4.1M	-$1.47	-$2.6M

Next report expected around November 27, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 28, 2025. Not a date the company has announced. See the report calendar

Where LEXX ranks in Health care

Revenue$705.9K

#583 of 646 in Health care · Bottom 10%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Lexaria Bioscience Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 9, 2026
Material agreement 8-K
September 1, 2026
Other event 8-K
August 17, 2026
Other event 8-K
August 10, 2026
Stock exchange listing notice 8-K
July 30, 2026
Shareholder rights changed 8-K
July 13, 2026
Quarterly report 10-Q · period to May 31, 2026Diluted EPS -$0.08 versus -$0.21.
April 13, 2026
Quarterly report 10-Q · period to February 28, 2026Revenue fell 89% to $20K versus the same quarter last year; diluted EPS -$0.06 versus -$0.15.
February 6, 2026
Stock exchange listing notice 8-K
January 28, 2026
Shareholder vote results 8-K
January 28, 2026
Employee stock plan registration S-8

Recent insider filings (Forms 3, 4 and 144): 10, the latest on March 18, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about LEXX

What does Lexaria Bioscience Corp. do?

Lexaria Bioscience Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LEXX.

Is Lexaria Bioscience Corp. profitable?

No. Over the twelve months to May 31, 2026 it reported a net loss of $7.7M on revenue of $194K.

How much revenue does Lexaria Bioscience Corp. make?

Over the twelve months to May 31, 2026 Lexaria Bioscience Corp. reported revenue of $194K. That is 68.5% less than a year earlier.

When did Lexaria Bioscience Corp. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 13, 2026. It covers the period to May 31, 2026. Its newest filing of any kind is the material agreement from September 9, 2026.

Similar companies

Compare LEXX with

Compare LEXX with any company

Follow LEXX

Get an email when Lexaria Bioscience Corp. files with the SEC: results, executive changes, material agreements and annual reports.

Follow LEXX: get an email when it files

Where the numbers come from

Financial figures are the values Lexaria Bioscience Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.